AMGEN INC.

AMGN · NASDAQ

Biological Product (except Diagnostic) Manufacturing · US

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

ESG Overview

Overall: A (High)

E: AS: BBG: BB

ESG grades from public dataset.

ESG data: Public Company ESG Ratings (CC BY-NC-SA 4.0)

Market Data

Price $375.20 -0.23 (-0.06%)

Market Cap$203.96B

P/E Ratio26.45

EPS$—

52W High$391.29

52W Low$261.43

Beta0.47

Data from Finnhub · Updated Mar 11, 2026